Search Videos and More
News
Shorter Course of Radiation Therapy is Safe for Patients with Early-Stage Breast Cancer who Have Undergone Mastectomy and Reconstruction
Cancer-related and physical outcomes were similar between longer and shorter regimens, but patients reported less burden on life and finances with shorter treatment regimen.
News
Final Overall Study Analysis Continues to Show Benefit of Sacituzumab Govitecan in Advanced HR+ Breast Cancer
A novel antibody-drug conjugate continues to demonstrate superior benefit for patients with HR+, HER2- metastatic breast cancer when compared to standard chemotherapy, according to a new study in The Lancet.
Document
Elacestrant for Advanced Estrogen Receptor-Positive Breast Cancer
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings on February 24 and May 5, 2023 to discuss recommendations for the use of elacestrant in patients with advanced estrogen receptor-positive breast cancer.
Video
ASCO 2023: Breast Cancer Research Presented by Paolo Tarantino, MD
Data from more than 8,000 patients with stage 1A triple-negative breast cancer finds improved 5-year breast-cancer specific survival in those treated with adjuvant chemotherapy whose tumors measured between 1-2 cm.
Video
ASCO 2023: Breast Cancer Research Presented by Jennifer Ligibel, MD
Women with breast cancer shed pounds thanks to telephone-based weight loss program, clinical trial finds.
Video
ASCO 2023: Breast Cancer Research Presented by Sara Tolaney, MD
Data shows antibody-drug conjugate offers significant survival benefit for patients with HR-positive/HER2-negative metastatic breast cancer.
News
New Study Suggests Simple Test Could Detect Breast and Ovarian Cancer Risk Without Genetic Sequencing
Researchers from Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Medical University of Lodz have found a way to detect increased cancer risk associated with BRCA1 and BRCA2 mutations without genetic sequencing, according to a new study in Nature Communications.
News
Dana-Farber Research Supports FDA Approval of New Therapy for Metastatic Breast Cancer
Sacituzumab govitecan, a novel antibody drug-conjugate therapy has been granted accelerated approved by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic HR+, HER2- breast cancer.
Video
SABCS 2022: Sara Tolaney, MD, MPH
Updated data from the APT trial shows that after 10 years of follow-up, adjuvant paclitaxel and trastuzumab confirm excellent long-term outcomes for small, node-negative HER2-positive breast cancer.
Video
SABCS 2022: Paolo Tarantino, MD
ATEMPT study shows that 5 years after treatment, 97% of patient's w/stage 1 HER2+ breast cancer treated w/TDM1 were alive and free from invasive disease and 98.3% had no recurrence of their cancer.
Video
SABCS 2022: Ann Partridge, MD, MPH
Ann Partridge, MD, MPH, led the study presented at the 2022 San Antonio Breast Cancer Symposium which showed most women participating in the study went on to deliver healthy babies.
Video
SABCS 2022: Rachel Freedman, MD, MPH
Rachel Freedman, MD, MPH, shared results from the TBCRC 022 study where Neratinib in combination w/T-DM1 showed promising activity in patients w/heavily pre-treated HER2+ breast cancer metastatic to the central nervous system.